Insmed reported $-160123000 in Net Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acelrx Pharmaceuticals ACRX:US USD -6750000 77.41M
Alimera Sciences ALIM:US USD -5257000 2.14M
Biomarin Pharmaceutical BMRN:US USD -249000 6.4M
Cytokinetics CYTK:US USD -137380000 4.93M
Dynavax Technologies DVAX:US USD 67.73M 3.92M
Gilead Sciences GILD:US USD 1.64B 149M
Heron Therapeutics HRTX:US USD -41908000 14.45M
Insmed INSM:US USD -160123000 28.98M
Mirati Therapeutics MRTX:US USD -202475000 28.91M
Novartis NVS:US USD 1.47B 107M
Regeneron Pharmaceuticals REGN:US USD 1.2B 118.6M
Sarepta Therapeutics SRPT:US USD -109244000 148.49M
Seattle Genetics SGEN:US USD -148171000 42.64M
Ultragenyx Pharmaceutical RARE:US USD -151833000 93.27M
Vertex Pharmaceuticals VRTX:US USD 818.9M 111.6M